Jerome H. Goldschmidt

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2013 · 474 citations · Full text

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology · 2020 · 430 citations · Full text

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2011 · 194 citations

Advanced Nsclc, Final Efficacy Results, Oncology +15

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt et al. · Lung Cancer · 2018 · 169 citations

Exploratory Analyses, Brain Metastases, Medicine +7

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara, Joachim von Pawel, Julien Mazières et al. · Journal of Thoracic Oncology · 2018 · 156 citations · Full text

Advanced Nsclc, Oncology, Medicine +4